Idexx Laboratories (NASDAQ: IDXX) and Immunomedics (NASDAQ:IMMU) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends.
Valuation and Earnings
This table compares Idexx Laboratories and Immunomedics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Idexx Laboratories||$1.97 billion||9.97||$263.14 million||$3.28||68.93|
|Immunomedics||$3.09 million||1,299.81||-$153.20 million||($0.81)||-29.63|
Idexx Laboratories has higher revenue and earnings than Immunomedics. Immunomedics is trading at a lower price-to-earnings ratio than Idexx Laboratories, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings and recommmendations for Idexx Laboratories and Immunomedics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Idexx Laboratories currently has a consensus target price of $216.50, indicating a potential downside of 4.24%. Immunomedics has a consensus target price of $31.50, indicating a potential upside of 31.25%. Given Immunomedics’ stronger consensus rating and higher probable upside, analysts plainly believe Immunomedics is more favorable than Idexx Laboratories.
Insider & Institutional Ownership
86.3% of Idexx Laboratories shares are held by institutional investors. Comparatively, 74.3% of Immunomedics shares are held by institutional investors. 2.6% of Idexx Laboratories shares are held by company insiders. Comparatively, 14.8% of Immunomedics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Volatility & Risk
Idexx Laboratories has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Immunomedics has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500.
This table compares Idexx Laboratories and Immunomedics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Idexx Laboratories beats Immunomedics on 8 of the 14 factors compared between the two stocks.
Idexx Laboratories Company Profile
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.
Immunomedics Company Profile
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody; and a collaboration agreement with University of Wisconsin Carbone Cancer Center to expand IMMU-132 into prostate cancer. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Receive News & Ratings for Idexx Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idexx Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.